Regeneron Pharmaceuticals, Inc. today announced that the New England Journal of Medicine (NEJM) published positive results from the Phase 3 trial of evinacumab in 65 patients with homozygous familial hypercholesterolemia (HoFH).

The NLA is excited to share that we will host our first-ever virtual Scientific Sessions! Due to current travel restrictions and gathering limitations in the city of Chicago, the NLA has made the difficult decision to rescope our 2020 Scientific Sessions into a fully virtual conference held live on Thursday, December 10 – Saturday, December 12, 2020.

There will be a reduced meeting registration for the virtual conference at a discounted rate of only $299.  Registration for the virtual sessions will open at the end of August.

August President's Message

Dr. Joseph Saseen takes a look ahead at what is to come for the NLA, including LipidPALOOZA in September!